Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
“The results of a recent trial of the direct renin inhibitor aliskiren in patients with type 2 diabetes mellitus plus chronic kidney disease or prevalent CVD did not find evidence that aliskiren reduced cardiovascular end points, including stroke.(241) In general, therefore, although the benefits of lowering BP as a me…”
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Modeling polypharmacy side effects with graph convolutional networks
Zitnik, M., Agrawal, M., & Leskovec, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty294 · Cited by 1,501
“…approach for multirelational link prediction in any multimodal network, it would be interesting to apply it to other domains andproblems, forexample, findingassociationsbetweenpatientoutcomes and comorbid diseases, or for identifying dependencies between mutant phenotypes and gene-gene interactions.”
BackgroundCheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Lurbe, E., Agabiti-Rosei, E., Cruickshank, J. K., Dominiczak, A., Erdine, S., Hirth, A., Invitti, C., Litwin, M., Mancia, G., Pall, D., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001039 · Cited by 1,379
“review of adult data from the ONTARGET [219], ALTITUDE [220] and VA NEPHRON-D [221] studies, the European Medicines Agency have formally recommended that no two drugs which act separately on the RAS should be used in combination because of risks of hyperkalemia, impaired kidney function and hypotension (www.”
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Evolving importance of kidney disease: from subspecialty to global health burden
Eckardt, K.-U., Coresh, J., Devuyst, O., Johnson, R. J., Köttgen, A., Levey, A. S., & Levin, A. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60439-0 · Cited by 1,159
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127
Contrast-Induced Acute Kidney Injury
McCullough, P. A., Choi, J. P., Feghali, G. A., Schussler, J. M., Stoler, R. M., Vallabahn, R. C., & Mehta, A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.099 · Cited by 1,067
“These data, combined with reports from CKD trials, suggest that although RASi are beneficial chronically, either too intensive RASi (ACEI þ ARB) or direct renin inhibition appears to have excessive toxicity in the setting of hospitalization, and probably in the setting of cardiac catheterization and PCI as well (29,30…”
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000597 · Cited by 902
“, 2012 (125) 23121378 Aim: Determine if addition of aliskiren as an adjunct to an ACEI or ARB reduces the risk of CV and renal events in pts with type 2 DM Inclusion criteria: • ≥35 y with type 2 DM • On ACEI or ARB • At least 1 of the following: persistent macroalbuminuria (urine microalbumin to creatinine ratio ≥200…”
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.06.010 · Cited by 947
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.005 · Cited by 920
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
“An ARB/ACEI combination more than doubles the risk of renal failure and hyperkalemia and is therefore not recommended (169,170).”
BackgroundBlood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2014) · Blood Pressure · doi:10.3109/08037051.2014.868629 · Cited by 739
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
“Also, in volume depleted states, risk for hyperkalemia increases (71,72,88).”
BackgroundBakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K., Cloutier, L., Gelfer, M., Lamarre-Cliche, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 684
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Heerspink, H. J. L., Parving, H.-H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F.-F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J. J. V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30772-x · Cited by 628
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 502
Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 479
Mente, A., O'Donnell, M., Rangarajan, S., Dagenais, G., Lear, S., McQueen, M., Diaz, R., Avezum, A., Lopez-Jaramillo, P., Lanas, F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30467-6 · Cited by 483
Brunström, M., & Carlberg, B. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6015 · Cited by 471
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“An ARB/ACEI combination more than doubles the risk of renal failure and hyperkalemia and is therefore not recommended (182,183).”
BackgroundMancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.812549 · Cited by 426
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401
“Patients with comorbid DM and HF may also benefit from the addition of mineralocorticoid receptor antagonist therapy to ACE-I/ARBs (43,44), although their use in combination with ACE-I and/or ARBs has been limited by concerns of worsening renal function and hyperkalemia (45).”
BackgroundWriting Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30313-9 · Cited by 338
Self-citationChanges in Diabetes-Related Complications in the United States
(2014) · New England Journal of Medicine · doi:10.1056/nejmc1406009 · Cited by 326
Gheorghiade, M., Böhm, M., Greene, S. J., Fonarow, G. C., Lewis, E. F., Zannad, F., Solomon, S. D., Baschiera, F., Botha, J., Hua, T. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.1954 · Cited by 328
“The bidirectional effect of aliskiren on 12-month all-cause death for patients with and without DM is notable given the results of the recent ALTITUDE study in which poor outcomes with aliskiren for patients with DM and concerns regarding renal dysfunction, hyperkalemia, hypotension, and stroke resulted in premature s…”
Self-citationRediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases
Argyropoulos, C. P., Chen, S. S., Ng, Y.-H., Roumelioti, M.-E., Shaffi, K., Singh, P. P., & Tzamaloukas, A. H. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00073 · Cited by 308
Laurent, S. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.026 · Cited by 301
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 304
Self-citationDiabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S. C., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 292
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“An ARB/ACEI combination more than doubles the risk of renal failure and hyperkalemia and is therefore not recommended (101,102).”
BackgroundDiabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Turakhia, M. P., Blankestijn, P. J., Carrero, J.-J., Clase, C. M., Deo, R., Herzog, C. A., Kasner, S. E., Passman, R. S., Pecoits-Filho, R., Reinecke, H., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy060 · Cited by 288
Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Abebe, K. Z., Chapman, A. B., Schrier, R. W., Braun, W. E., Steinman, T. I., Winklhofer, F. T., Brosnahan, G., Czarnecki, P. G., Hogan, M. C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402686 · Cited by 291
Mennuni, S., Rubattu, S., Pierelli, G., Tocci, G., Fofi, C., & Volpe, M. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.55 · Cited by 292
Tuttle, K. R., Brosius, F. C., Adler, S. G., Kretzler, M., Mehta, R. L., Tumlin, J. A., Tanaka, Y., Haneda, M., Liu, J., Silk, M. E., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx377 · Cited by 284
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H. J. L., & Schall, T. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00261-2 · Cited by 273
Sodium Intake in Populations: Assessment of Evidence
Strom, B. L., Yaktine, A. L., Oria, M. P., & Nutrition Board (2013) · Cited by 297
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
Lee, H.-Y., Shin, J., Kim, G.-H., Park, S., Ihm, S.-H., Kim, H. C., Kim, K.-I., Kim, J. H., Lee, J. H., Park, J.-M., et al. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0124-x · Cited by 264
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Hyperkalemia: pathophysiology, risk factors and consequences
Hunter, R. W., & Bailey, M. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz206 · Cited by 253
Inflammatory Targets in Diabetic Nephropathy
Donate-Correa, J., Luis-Rodríguez, D., Martín-Núñez, E., Tagua, V. G., Hernández-Carballo, C., Ferri, C., Rodríguez-Rodríguez, A. E., Mora-Fernández, C., & Navarro-González, J. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020458 · Cited by 245
Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial
Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070942 · Cited by 262
Barrera-Chimal, J., Lima-Posada, I., Bakris, G. L., & Jaisser, F. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00490-8 · Cited by 252
Hypertension in Chronic Kidney Disease
Hamrahian, S. M., & Falkner, B. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2016_84 · Cited by 246
Ma, J., Li, Y., Yang, X., Liu, K., Zhang, X., Zuo, X., Ye, R., Wang, Z., Shi, R., Meng, Q., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01430-7 · Cited by 243
“Conversely, it was associated with a higher incidence of adverse effects compared to ARB therapy alone.(242) According to that, the prospect of targeting (P)RR in the treatment of hypertension is not as good as AT1R.”
Background2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
McMurray, J. J. V., Krum, H., Abraham, W. T., Dickstein, K., Køber, L. V., Desai, A. S., Solomon, S. D., Greenlaw, N., Ali, M. A., Chiang, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514859 · Cited by 249
Self-citationMakani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Warren, A. M., Knudsen, S. T., & Cooper, M. E. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1624721 · Cited by 245
“In subjects with type 2 diabetes, macroalbuminuria, and reduced kidney function (eGFR ≤60mL/min/1.73 m2), addition of finerenone to ACEi or ARB treatment dosedependently reduced albuminuria, with a small incidence of hyperkalemia of 2–3% [16].”
ResultInfluentialThe Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
Kanasaki, K., Taduri, G., & Koya, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00007 · Cited by 227
Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.